All aspects of clinical trials present significant risk. The Trialytics approach lessens these risks and reduces waste by applying an evidence base of healthcare data to clinical trial strategies. Our approach markedly reduces the risks, time, and cost of protocol design, site selection, and patient recruitment.

According to CenterWatch, approximately 94% of U.S. clinical trials are delayed; typical reasons include poor site performance and ineffective recruitment methods. In the U.S. there are too few research sites, leading to overuse of many known investigators. At Trialytics we leverage electronic healthcare data to redefine clinical trial strategies. Using proprietary algorithms, Trialytics harnesses this data to help develop and execute Phase II, Phase III, and post-marketing trials.

Trialytics specializes in applying advanced healthcare data analytics to clinical development strategies to optimize protocol designs, reduce the risks of site selection, locate the right patients, and drive patient recruitment locally through primary care pathways.